Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …

Radiotherapy, a mainstay of first‐line cancer treatment, suffers from its high‐dose radiation‐
induced systemic toxicity and radioresistance caused by the immunosuppressive tumor …

A challenge in oncology is to rationally and effectively integrate immunotherapy with
traditional modalities, including radiotherapy. Here, we demonstrate that radiotherapy …

A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

In the development of central nervous system (CNS) drugs, the blood–brain barrier (BBB)
restricts many drugs from entering the brain to exert therapeutic effects. Although many …

Novel approaches are needed to boost the efficacy of immune checkpoint blockade (ICB)
therapy. Ataxia telangiectasia mutated (ATM) protein plays a central role in sensing DNA …

Antitumor therapeutic strategies that fundamentally rely on the induction of DNA damage to
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …

The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

DNA damage response (DDR) pathway prevents high level endogenous and environmental
DNA damage being replicated and passed on to the next generation of cells via an …